Core Viewpoint - The company Baiotai (688177.SH) has signed a licensing and commercialization agreement with STADA for its BAT1806 (Tocilizumab) injection, granting STADA exclusive commercialization rights in several regions, including the EU, Switzerland, the UK, parts of Europe, the MENA region, and some CIS countries [1][2] Group 1: Agreement Details - The total amount of upfront and milestone payments can reach up to €136 million, which includes an upfront payment of €8.5 million and milestone payments not exceeding €127.5 million, along with a double-digit percentage of net sales as revenue sharing [1] - BAT1806 (Tocilizumab) is a biosimilar developed according to guidelines from the NMPA in China, FDA in the US, and EMA in Europe, targeting the IL-6 receptor [1] Group 2: STADA Overview - STADA is a well-established European pharmaceutical company headquartered in Germany, focusing on three strategic pillars: consumer health, generics, and specialty pharmaceuticals [2] - In the fiscal year 2024, STADA achieved a group sales revenue of €4.059 billion, with an adjusted EBITDA of €886 million, and employs approximately 11,649 people globally [2] - The collaboration aims to rapidly convert the company's research achievements into economic benefits through commercial partnerships and licensing, enhancing the company's core competitiveness [2]